Drugs / Henagliflozin Proline
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06221059 | Mar 2024 → Mar 2025 | chronic kidney disease | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06417489 | May 2024 → May 2026 overdue | type 2 diabetes mellitus | Peking University First Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Henagliflozin Proline | “Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid.” NCT06417489 ↗ |